TERT, a promoter of CNS malignancies by Patel, Bhuvic et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
TERT, a promoter of CNS malignancies 
Bhuvic Patel 
Washington University School of Medicine in St. Louis 
Rukayat Taiwo 
Stanford University 
Albert H. Kim 
Washington University School of Medicine in St. Louis 
Gavin P. Dunn 
Washington University School of Medicine in St. Louis 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Recommended Citation 
Patel, Bhuvic; Taiwo, Rukayat; Kim, Albert H.; and Dunn, Gavin P., ,"TERT, a promoter of CNS malignancies." 
Neuro-Oncology Advances.,. . (2020). 
https://digitalcommons.wustl.edu/open_access_pubs/9646 
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been 
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. 
For more information, please contact engeszer@wustl.edu. 
Neuro-Oncology Advances
2(1), 1–11, 2020 | doi:10.1093/noajnl/vdaa025 | Advance Access date 28 February 2020
1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. 
For commercial re-use, please contact journals.permissions@oup.com
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Bhuvic Patel, Rukayat Taiwo, Albert H. Kim, and Gavin P. Dunn
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA (B.P., 
A.H.K., G.P.D.); Department of Neurological Surgery, Stanford University, Stanford, California, USA (R.T.); Andrew 
M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University 
School of Medicine, St. Louis, Missouri, USA (G.P.D.)
Corresponding Author: Gavin P. Dunn, MD, PhD, Department of Neurosurgery, Washington University School of Medicine,  
660 S. Euclid Ave., St. Louis, MO 63110, USA (gpdunn@wustl.edu).
Abstract
As cells replicate their DNA during mitosis, telomeres are shortened due to the inherent limitations of the DNA 
replication process. Maintenance of telomere length is critical for cancer cells to overcome cellular senescence 
induced by telomere shortening. Telomerase reverse transcriptase (TERT) is the rate-limiting catalytic subunit of 
telomerase, an RNA-dependent DNA polymerase that lengthens telomeric DNA to maintain telomere homeostasis. 
TERT promoter mutations, which result in the upregulation of TERT transcription, have been identified in several 
central nervous system (CNS) tumors, including meningiomas, medulloblastomas, and primary glial neoplasms. 
Furthermore, TERT promoter hypermethylation, which also results in increased TERT transcription, has been ob-
served in ependymomas and pediatric brain tumors. The high frequency of TERT dysregulation observed in a va-
riety of high-grade cancers makes telomerase activity an attractive target for developing novel therapeutics. In this 
review, we briefly discuss normal telomere biology, as well as the structure, function, and regulation of TERT in 
normal human cells. We also highlight the role of TERT in cancer biology, focusing on primary CNS tumors. Finally, 
we summarize the clinical significance of TERT promoter mutations in cancer, the molecular mechanisms through 
which these mutations promote oncogenesis, and recent advances in cancer therapies targeting TERT.
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One hallmark of cancer is the ability of cancer cells to replicate 
indefinitely.1 This replicative potential runs counter to Hayflick’s 
rule, which imposes a limit on the replicative potential of a 
normal cell.2 This limitation is a result of the directionality of 
DNA polymerase, which causes shortening of chromosome 
ends after each replicative cycle, leading to cellular senescence. 
The addition of telomeres to the ends of chromosomes allows 
for successive replicative cycles without chromosomal DNA 
shortening. Telomeres, which consist of noncoding TTAGGG 
nucleotide repeats, protect the ends of chromosomes from de-
terioration and end fusion to other chromosomes.3,4 Telomeres 
are protected from DNA damage by binding to proteins that 
create a shelterin complex.4 The telomerase enzyme is an RNA-
dependent DNA polymerase that lengthens telomeric DNA to 
maintain telomere homeostasis.5 Telomerase reverse transcrip-
tase (TERT) is the rate-limiting catalytic subunit of telomerase.6
Telomerase activity is highly regulated. In most somatic 
cells with finite proliferative potential, telomerase activity is 
downregulated through epigenetic regulation of the TERT pro-
moter.7,8 Telomeres in these somatic cells shorten with suc-
cessive mitoses, ultimately triggering cellular senescence.9 In 
contrast, in stem cells and proliferative cells of self-renewing tis-
sues, telomerase activity is not downregulated and counteracts 
the shortening of telomeres, allowing for increased replicative 
potential.
Cancer cells must maintain telomere length to circumvent 
cellular senescence. Telomerase upregulation can be found 
in 90% of malignancies, although the mechanism of acti-
vation is not always known.9 One well-known mechanism, 
upregulation of TERT transcription, often occurs through 
TERT promoter mutations. Such mutations have been 
found in meningioma, glioblastoma, medulloblastoma, and 
TERT, a promoter of CNS malignancies
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non-central nervous system (CNS) cancers.9–12 Another 
well-described mechanism of TERT upregulation is TERT 
promoter methylation, which paradoxically results in in-
creased TERT expression in glioblastoma, ependymoma, 
and medulloblastoma, along with several non-CNS 
cancers.13–17
In this review, we outline normal telomere biology and 
regulation of TERT. We discuss the mechanisms of TERT 
upregulation and its role in cancer, focusing on glioblas-
toma and other CNS tumors. We also describe the clinical 
and prognostic relevance of TERT mutations in CNS tu-
mors. Finally, we discuss therapies that might target can-
cers with aberrant TERT upregulation.
Normal Telomere Biology
Telomeres span approximately 10–20  kb at the end of 
human chromosomes.3,4,18 The noncoding repeats in telo-
meres bind proteins that form the shelterin complex.3,4,18 
Telomeres also consist of a 150–200 nucleotide, G-rich, 
single-stranded overhang, which ends with a 3′-OH group 
that is recognized by TERT.3,4 This single-stranded overhang 
is protected from the DNA double-strand break repair ma-
chinery by folding back on itself to form the so-called T-loop 
and by recruitment of the shelterin complex.3,18 The forma-
tion of this nucleoprotein structure protects chromosome 
ends from nonhomologous end joining and regulates the 
access of telomerase to telomeres.
Telomeres shorten with DNA replication due to an ina-
bility to fill in the gap with complementary DNA on the 5′-
end of the DNA strand after the RNA primer is removed 
during replication, termed the “end replication problem.” 19 
The loss of telomeric repeats with successive replication 
cycles leads to an inability of the telomere to form the 
T-loop or recruit the shelterin complex. This causes a loss 
of chromosomal protection that leads to the formation of 
end-to-end chromosomal fusions and loss of cell viability.3
A human telomere contains enough repeats to withstand 
the loss of length for approximately 50–90 replication 
cycles in the absence of telomere elongation mechanisms.4 
Most cells undergoing continuous division, such as stem 
cells, overcome the end replication problem by expressing 
telomerase. The telomerase complex, which is comprised 
of TERT and an RNA molecule encoded by the telomerase 
RNA component (TERC) gene, binds to telomeres at 
the end of the single-telomere overhang.3 Once TERT is 
bound, its enzymatic activity elongates the telomere, thus 
allowing the cell to undergo additional DNA replication 
cycles (Figure 1).
Alternative lengthening of telomeres (ALT) is another 
mechanism of telomere elongation. While most immortal 
cell lines exhibit telomerase activity, some cell lines, in-
cluding 10% of cancer lines, exhibit no telomerase activity 
but still have elongated telomeres as a result of ALT.20 
Although the details have not been elucidated, it is postu-
lated that lengthening by ALT occurs by using recombina-
tion to copy telomeres from other chromosomes or from 
the same chromosome.21,22 Whole exome sequencing of 
glioblastomas with wildtype IDH and TERT  promoter iden-
tified an ALT positive subgroup of tumors with ATRX or 
SMARCAL1 mutations. These mutations are mutually ex-
clusive and confer a similar overall survival to TERT pro-
moter mutations, suggesting that ALT plays an important 
role in glioblastoma.23
More recently, telomeres have been found to have 
functions other than DNA end protection, such as reg-
ulation of gene expression through transcriptional si-
lencing of genes.24 Although the mechanism is poorly 
understood, the conformation of telomeric DNA, in-
cluding structures such as the T-loop, is also thought to 
contribute to telomere function. Additionally, RNA tran-
scribed from telomeric DNA, so-called telomeric repeat-
containing RNA, has been implicated in a variety of 
processes such as regulation of telomerase, heterochro-

















Fig. 1 Telomere elongation. After recruitment to the telomere by the shelterin complex, TERT catalyzes the addition of the telomere repeats 
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TERT Structure, Function, and 
Regulation
The TERT protein is comprised of 4 domains: the telom-
erase essential N-terminal domain (TEN), the reverse 
transcriptase domain (RT), the telomerase RNA-binding 
domain (TRBD), and the C-terminal extension do-
main.4,25 The TEN domain binds RNA and telomeric DNA 
and contributes to catalysis.26 The RT domain contains 
an insertion in the finger domain that distinguishes it 
from other reverse transcriptases.25,26 TERT binds the 
TERC-encoded RNA in the TRBD to form the telomerase 
ribonucleoprotein.
TERT is located at chromosome 5p15.33 in humans, 
while TERC is located at chromosome 3q26.24 TERC pro-
vides the template for synthesis of telomeric repeats, 
whereas TERT is the catalytic component of telomerase. 
The presence of TERT and TERC alone is sufficient for telo-
mere elongation in vitro, but in vivo function also requires 
other components that serve additional roles, such as 
regulating attachment to telomeres and trafficking of te-
lomerase components into the nucleus.4,24,27
The TERT gene is 40-kb long and consists of 15 in-
trons and 16 exons with a 260-bp promoter core. The 
TERT promoter region contains GC boxes that bind the 
zinc finger transcription factor SP1, which increases TERT 
transcription, and E-boxes that bind both transcriptional 
enhancers and repressors.4,7,24 The GC-rich areas around 
the transcription start site are also regions of epigenetic 




Analysis of data from metastatic melanoma patients 
by Huang et al.28 identified 2 recurrent C>T mutations in 
the TERT promoter region -124 (C228T) and -146 (C250T) 
base pairs from the transcriptional start site in 71% of pa-
tients. Subsequent screening for TERT promoter muta-
tions found varying prevalence among different cancers 
(Table 1).29 TERT promoter mutations are associated with 
increased TERT expression and telomerase activity.10 
Both commonly observed mutations (C228T and C250T) 
generate identical de novo binding sites for the E-twenty-
six (ETS) family of transcription factors.28 Even though 
there are 27 ETS transcription factors that all bind to sim-
ilar sequences, only GA Binding Protein Transcription 
Factor Subunit Alpha (GABPA) selectively binds the mu-
tant TERT promoter and not the wildtype version in sev-
eral cancers.9,30 GABPA functions as a homodimer or as 
a heterotetramer with GABPB. The TERT promoter mutant 
sites cooperate with native ETS sites to recruit GABPA/B 
as a heterotetramer and activate TERT transcription.30 In 
contrast, a study using melanoma cell lines found only 
minimal binding of the GABPA homodimer to the mutant 
TERT promoter.31
Increased TERT transcription in the setting of TERT pro-
moter mutation has also been found to occur in an NF-κβ-
dependent manner. Unlike the C228T mutation, the C250T 
mutation creates a binding site for the NF-κβ subunit p52, 
allowing for the cooperative binding of NF-κβ and ETS1/2 
to activate transcription.32 Thus, despite having similar 
downstream effects, the 2 canonical TERT promoter muta-
tions may distinctly alter TERT expression.  
Table 1 Continued
TERT Promoter Mutations in CNS Neoplasms
TERT promoter mutations have been identified in CNS 
tumors, including primary glial neoplasms (up to 80%), 
medulloblastomas (20%), and meningiomas (6.4–11%).29,33–
40 As with other cancers, the 2 most common promoter 
mutations are C228T and C250T, which occur in a mutually 
exclusive fashion. The mutation frequency varies by sub-
type for each of these tumors.
In adult primary glial neoplasms, the frequency of TERT 
promoter mutations varies by WHO grade (Figure  2). 
Glioblastoma (WHO grade IV) has a high frequency of 
mutations (80%). WHO grade II and III lesions, such as 
oligodendrogliomas, have a relatively lower frequency of 
TERT mutations (60–70%), and WHO grade I tumors, such 
as astrocytomas, have the lowest frequency of TERT mu-
tations (30–40%).29,33,37,39 In patients with primary glial 
neoplasms, particularly glioblastoma, TERT promoter mu-
tations were associated with co-mutations in epidermal 
growth factor receptor (EGFR), CDKN2A/B, and phos-
phatase and tensin homolog.40 Data from multi-sector 
sequencing of glioblastoma tumors revealed TERT pro-
moter mutations to be clonal in all tumor sectors, sug-
gesting that these mutations represent an early oncogenic 
event in this cancer.41,42
In patients with meningiomas, TERT promoter muta-
tions are associated with higher grade lesions (1.7% WHO 
grade I, 5.7% WHO grade II, and 20% WHO grade III) and 
with advancing tumor grade upon recurrence.35,38 In pa-
tients with medulloblastoma, although the overall muta-
tion frequency is reported as 20%, the frequency of TERT 
promoter mutations in the wingless (WNT) and sonic 
hedgehog (SHH) subtypes has been reported to be as high 
as 31% and 83%, respectively.33,36
TERT Promoter Hypermethylation
TERT promoter hypermethylation has more re-
cently been identified as an additional contributor 
to TERT dysregulation in cancer cells.13–17 Promoter 
hypermethylation may represent an alternative means of 
TERT upregulation or may work in conjunction with TERT 
promoter mutations to increase TERT expression in cancer 
cells. Hypermethylation of the promoter region would typ-
ically be expected to result in transcriptional silencing. 
However, in the case of the TERT promoter, a region termed 
the TERT hypermethylated oncological region (THOR) has 
been identified as a site of methylation that causes an 
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is a 433-bp region that contains 52 CpG sites located imme-
diately upstream of the TERT core promoter.17 Importantly, 
hypermethylation of THOR results in increased TERT ex-
pression regardless of TERT promoter mutation status. 
Furthermore, when THOR is unmethylated, the activating 
effects of TERT promoter mutations appear to be repressed 
compared to when THOR is hypermethylated.17 These find-
ings suggest that THOR hypermethylation represents an in-
dependent mechanism of increased TERT expression from 
TERT promoter mutations.
Remarkably, the frequency of THOR hypermethylation 
may be as high as the frequency of TERT promoter muta-
tions in some cancers. Indeed, more than 70% of prostate, 
breast, hematological, and colon cancers are charac-
terized by THOR hypermethylation.17 In general, the fre-
quency of THOR hypermethylation appears to be greater 
in cancers with a low frequency of TERT promoter mu-
tations. Nonetheless, THOR hypermethylation has been 
observed with relatively high frequency even in cancers 
with a high frequency of promoter mutations and has 
been found to be approximately 63% in CNS tumors.17
Impact of TERT Dysregulation in Cancer Cells
All cancer cells acquire molecular aberrations that confer 
the properties of replicative immortality, sustained pro-
liferative signaling, evasion of growth suppressors, 
resistance to cell death, angiogenesis, invasion, and 
  
Table 1 Summary of the Frequency of TERT Promoter Mutations in 
Central Nervous System Tumors




 Primary glioblastoma 70–80%12







 Atypical fibroxanthoma 93%11
 Pleomorphic dermal sarcoma 76%11
 Squamous cell carcinoma 60%11
 Basal cell carcinoma 47.4%11
 Merkel cell carcinoma 10.2%11
Melanomas
 Non-acral melanoma 35–80%12
 Conjunctival melanoma 30–40%12
 Mucosal melanoma 10–15%12
 Acral melanoma 5–10%12
 Uveal melanoma 0–1%12
Thyroid cancers
 Poorly differentiated thyroid carcinoma 42.9%11
 Anaplastic thyroid carcinoma 39.2%11
 Follicular thyroid carcinoma 17.1%11
 Atypical follicular thyroid adenoma 16.7%11
 Hürthle cell carcinoma 13.1%11
 Differentiated thyroid carcinoma 12.1%11
 Papillary thyroid carcinoma 11.0%11
Gynecological cancers 
 Ovarian clear cell carcinoma 15.9%11
 Squamous cell carcinoma of the cervix 9.9%11
 Endometrial carcinoma 6.6%11
 Ovarian low-grade serous carcinoma 4.9%11
Urological cancers  
 Micropapillary urothelial carcinoma 100%12
 Squamous cell carcinoma of the bladder 80%12
  Infiltrating urothelial carcinoma with  
glandular differentiation 
72%12
 Urothelial carcinoma 60–70%12
 Renal pelvic carcinoma 45%12
 Ureter carcinoma 19%11
 Urethral carcinoma 15–20%12
 Inverted urothelial papilloma 15%12
 Chromophobe renal cell carcinoma 13%12
 Clear cell renal cell carcinoma 5–10%12
 Renal cell carcinoma, unclassified 8%12




  Combined hepatocellular 
cholangiocarcinoma 
45%12
 Hepatocellular carcinoma 41.2%11
 Gallbladder cancer 4%12
 Intrahepatic cholangiocarcinoma 0–5%12
 Esophageal squamous cell carcinoma 0–2%12
 Gastric cancer 0%11
Pulmonary cancers
 Malignant pleural mesothelioma 15.2%11
 Lung and non-small cell lung carcinomas 0–2%11
Head and neck cancers
 Laryngeal carcinoma 27.2%11
 Squamous cell carcinoma of head and neck 16.3%11
Soft tissue cancers
 Myxoid liposarcoma 69.4%11
 Chondrosarcoma 50%†11
 Fibrosarcoma 33.3%†11
 Solitary fibrous tumor 24.1%11
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metastasis.1,45 Telomere length plays a complex role in 
oncogenesis. Critical shortening of telomeres results in 
increased rates of oncogenic chromosomal alterations 
such as deletions and chromosomal end fusions. At the 
same time, the shortening of telomeres activates the 
normal regulatory pathways that result in cellular senes-
cence or even cell death. In 90% of cancers, telomerase 
upregulation is critical to achieve proliferative immor-
tality.4,20,24 The TERT subunit catalyzes the rate-limiting 
step of telomerase, making the TERT gene a logical target 
for upregulation in cancer cells. Indeed, Hahn et  al.46 
demonstrated that ectopic expression of TERT, in addi-
tion to key oncogene expression and tumor suppressor 
dysfunction, is required for the transformation of human 
somatic cells into tumorigenic cells.
Analysis of 1230 tumors from 60 cancer types by 
Killela et al.29 found 2 distinct groups of cancers—those 
with a high (≥15%) or a low (<15%) frequency of TERT 
promoter mutations. The 9 cancers in the high-frequency 
group all originated from tissues with low self-renewal 
and included tumors such as medulloblastoma and pri-
mary gliomas. This finding led to the hypothesis that 
TERT promoter mutations primarily benefit cancer cells 
originating from tissues with low self-renewal poten-
tial.8 In cancers originating from the hematopoietic 
system or gastrointestinal tract, for example, TERT pro-
moter mutations would be predicted to have less of an 
impact on TERT expression since these tissues already 
express TERT. Accordingly, the frequency of TERT pro-
moter mutations in these cancers is low.8,10,29 In con-
trast, cancers arising from cells with low replicative 
potential that do not express TERT, such as astrocytes 
or melanocytes, would gain a replicative advantage over 
other cells via aberrant overexpression of TERT resulting 
from promoter mutations.10,28,29,40,47 Although this expla-
nation is corroborated by the relative frequency of these 
mutations observed in several cancers, there are some 
notable exceptions, including non-melanoma skin can-
cers, which have a high frequency, of TERT promoter 
mutations.48 These exceptions suggest the possibility 
that an oncologic advantage may be conferred through 
alternative functions of the TERT protein or of telomeres 
themselves.
Indeed, while TERT promoter mutations are associated 
with increased telomerase expression in some cancers, 
there is growing evidence that TERT promoter mutations 
are not always associated with longer telomeres.39 In 
human fibroblast cell lines that maintain long telomeres 
through ALT, the expression of oncogenic H-RAS led to 
inefficient tumorigenicity. However, overexpression of 
TERT in addition to H-RAS resulted in robust malignant 
transformation of ALT fibroblasts, suggesting that TERT 
may have telomere-lengthening-independent roles in 
tumor initiation and/or maintenance.49 Additionally, Chiba 
et al.50 found that during malignant transformation in mel-
anoma, TERT promoter mutation-driven telomerase ex-
pression does not prevent telomere shortening. Findings 
such as these have led to the hypothesis that increased 
telomerase expression may allow for the persistence of 
genetically unstable clones by maintaining telomeres just 
above a critically short length, thus avoiding cellular se-
nescence while also promoting rapid disease evolution.
TERT may also have functions entirely independent 
of telomere biology. For example, TERT is capable of 
  
Grade II Grade III Grade IV
Oligodendroglioma
Astrocytoma
IDH mut, TERTp mut (72%)
IDH mut, 1p19q codel (71%)
IDH mut, TERTp mut (75%)
IDH mut, 1p19q codel (71%)
IDH mut, TERTp wt (42–74%)
IDH wt, TERTp mut (6–28%)
IDH mut, TERTp wt (35–63%)
IDH wt, TERTp mut (19–30%)
IDH mut, TERTp wt (6–16%)
IDH wt, TERTp mut (54–74%)Precursor cell
Fig. 2 Frequency of TERT promoter mutation, IDH mutation, and 1p19q co-deletion in glioma. The frequency of TERT promoter mutations (TERTp 
mut) increases with increasing grade of primary glial neoplasms. The presence of TERT promoter mutations in combination with other commonly 
observed genetic abnormalities in gliomas, such as IDH mutation (IDH mut) and chromosome 1p19q co-deletion (1p19q codel), has both diag-
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performing RNA-dependent RNA polymerase (RdRP) func-
tions via its association with BRG1, an SWI/SNF-related 
chromatin remodeling protein, and nucleostemin, a GTP-
binding protein, forming the TERT–BRG1–NS complex 
(TBN complex). The TBN complex synthesizes double-
stranded RNAs that are processed into short-interfering 
RNAs that regulate heterochromatin assembly and mitotic 
progression.51 Inhibitors targeting these non-canonical 
functions of TERT serve as promising anticancer agents. 
One such inhibitor, Eribulin, that targets the RdRP activity 
of TERT is discussed in a later section.
Additionally, in an in vitro model, TERT knockout so-
matic cells were reprogrammed into pluripotent stem 
cells by the introduction of an enzymatically inactive 
TERT mutant, suggesting that TERT may maintain a 
stem-like cell state independently of telomere length-
ening.52 Potential mechanisms of this function include di-
rect modulation of the Wnt/β-catenin signaling pathway 
and increased EGFR expression.53,54 Finally, TERT may pro-
mote invasion and metastasis of cancer cells by altering 
the expression of extracellular matrix remodeling and 
epithelial-to-mesenchymal transition related genes.55–57
Clinical Significance of Aberrant TERT 
Expression
TERT promoter mutations occur in specific clinical and phe-
notypic subtypes of various cancers. They are found mainly 
in adult rather than pediatric tumors and are sometimes 
associated with more aggressively behaving subtypes of 
cancers including melanomas, gliomas, meningiomas, and 
hepatocellular carcinomas.4,33,38,40 Given the normal age-
dependent shortening of telomeres, it is unsurprising that 
TERT promoter mutations are associated with increased 
age at diagnosis for these cancers. The clinical impact of 
these mutations has been most extensively studied in mel-
anomas, where TERT promoter mutations were found to 
be associated with markers of poor prognosis, such as in-
creased Breslow thickness and metastasis, and with poor 
overall survival and disease-free progression.4,29,47 The clin-
ical impact of these mutations has similarly been studied in 
primary CNS tumors, including gliomas and meningiomas.
Prognostic Impact of TERT Promoter Mutations 
on Gliomas
Several genetic aberrations that modify prognosis have 
been discovered in gliomas. Mutations in isocitrate de-
hydrogenase 1 (IDH1) are associated with lower histo-
logical grade, prolonged progression-free survival, and 
increased response to chemoradiotherapy.58 These muta-
tions tend to also be associated with secondary gliomas, 
which progress from an antecedent lower grade to higher 
grade disease.37,59 Meanwhile, 1p and 19q co-deletions 
are associated with better survival in oligodendrogliomas 
and also correlate with IDH1 mutations.60 Methylguanine 
methyltransferase (MGMT) promoter methylation is yet 
another critical determinant of prognosis and treatment re-
sponse. Glioblastomas with MGMT promoter methylation 
have been shown to have a more favorable treatment 
response to alkylating agents with a resultant survival 
benefit.61 The various combinations of these genetic abnor-
malities have identified subtypes of gliomas with clinically 
distinct behavior. Factoring the presence of TERT promoter 
mutational status into these combinations may allow for 
better characterization of gliomas, with implications for 
precision medicine.
TERT promoter mutation frequency increases with 
increasing WHO grade in gliomas (Figure 2).29,37 Across all 
subtypes of glioma, TERT promoter mutations are inde-
pendently associated with worse overall survival.37,62,63 The 
frequency of mutations is inversely correlated with IDH1 
mutation in all gliomas but positively correlated with 1p 
and 19q co-deletions in oligodendrogliomas.
The presence of TERT promoter mutations in combina-
tion with IDH1 mutations changes overall survival in glioma 
patients. Gliomas with TERT promoter mutations without 
IDH1 mutation have worse overall survival than those with 
wildtype TERT promoter and IDH1 mutation. Meanwhile, 
gliomas with wildtype TERT promoter and wildtype IDH1 
have an intermediate overall survival. Paradoxically, 
gliomas with both TERT promoter mutation and IDH1 mu-
tation have improved overall survival compared to patients 
with wildtype TERT promoter and IDH1 mutation.37,62,63 
Interestingly, concomitant mutations in TERT and IDH1 
occur at nearly the same frequency as concomitant muta-
tions in IDH1 and 1p and 19q co-deletions, providing further 
insight into the molecular etiology of oligodendrogliomas.64 
Therefore, the improved survival in this group of patients 
is not a result of biological interaction between these mu-
tations but rather identification of a lower grade glioma.37,63 
This is corroborated by the fact that the small group of 
gliomas with co-mutations in TERT promoter and IDH1 
without 1p and 19q co-deletions correspond to gliomas with 
aggressive behavior and survival similar to those with TERT 
promoter mutations and IDH1 wildtype.37,62,63
The important role of TERT promoter mutations on prog-
nosis and clinical behavior is highlighted by the recently 
published cIMPACT-NOW update 3, which recommends 
that IDH wildtype grade II and III infiltrating astrocytomas 
with TERT promoter mutations, EGFR amplification, and/or 
chromosome 7 gain and 10 loss be graded as WHO grade 
IV.65 Although not currently graded as WHO grade IV tu-
mors, these tumors have clinical, histopathological, and 
radiographic behavior similar to WHO grade IV tumors.63,66 
Appropriate stratification of patients based on the ge-
netic profile of their gliomas is thus critically important 
in informing how aggressively they should be treated. To 
this end, Shankar et al.67 developed a rapid intraoperative 
genotyping assay to detect TERT promoter and IDH1 
mutational status in WHO grade II and III gliomas. This 
intraoperative molecular information has the potential to 
aid in real-time surgical decision making and may allow for 
precision therapy at the time of surgery.
Prognostic Impact of TERT Promoter Mutations 
on Other Primary CNS Tumors
TERT promoter mutations are associated with higher 
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the mutation has been associated with a more aggressive 
natural history. Grade I tumors with the mutation were as-
sociated with a higher rate of recurrence with increased 
risk of progression to a higher grade in recurrent tumors. 
Analysis of recurrent meningiomas without malignant pro-
gression revealed a lack of the TERT mutation compared 
to recurrent meningiomas with malignant progression.35 
Similarly, grade II and III tumors with TERT mutations were 
associated with higher recurrence rates as well as shorter 
time to progression and/or recurrence.38,42 In high-grade 
meningiomas, the TERT promoter mutation was associ-
ated with worse overall survival (2.7 years vs 10.8 years).42
The TERT promoter mutation is the most common 
recurrent somatic point mutation observed in 
medulloblastomas and occurs primarily in adults with 
the SHH and WNT subtypes.34,36 The distribution of 
promoter mutation frequency among the various sub-
types of medulloblastoma is not surprising given that 
the SHH subtype is the most common subtype in adult 
medulloblastoma patients and, as observed with other 
cancers, the mutation has a higher frequency among 
older patients. Interestingly, unlike with other cancers, 
TERT promoter mutations in SHH medulloblastomas are 
associated with a more favorable overall survival and 
with a lower incidence of metastatic disease on presen-
tation. Group  4 medulloblastomas with the TERT pro-
moter mutation follow the pattern observed in gliomas 
and meningiomas, with worse overall survival than 
those with wildtype TERT promoter.34 In the WNT and 
group 3 medulloblastoma subtypes, the TERT promoter 
mutation does not appear to make a difference in overall 
survival. While the underlying biology explaining these 
survival differences is poorly understood, stratification 
of patients based on mutation status can inform discus-
sions of prognosis and targeted therapeutics as they be-
come available in the future.
TERT as a Therapeutic Target
The high frequency of TERT promoter mutations in can-
cers makes telomerase activity an attractive target for the 
development of therapeutic interventions. Additionally, 
normal cells typically have lower telomerase activity and 
maintain longer telomeres than cancer cells, allowing 
cancer cells to be preferentially targeted by telomerase-
inhibiting therapies. Despite this, there are challenges 
to targeting TERT in the treatment of cancers. Telomere 
shortening to a length that induces cell death requires 
multiple cell cycles after TERT inhibition is initiated. This 
results in a lag to the response of these therapies during 
which time tumor burden increases. Furthermore, since 
TERT is normally highly expressed in rapidly dividing 
cells, targeting TERT can have side effects, particularly on 
the hematopoietic system.24 One strategy to overcome 
these challenges may involve the use of other, more im-
mediately acting treatments in conjunction with TERT-
based therapies.
To date, no FDA-approved treatments targeting telom-
erase are available, but approaches including use of small 
molecule inhibitors, antisense oligonucleotides, immu-
notherapy, and G-quadruplex stabilizers are being in-
vestigated, with some therapies in various clinical trial 
phases.24 Promising approaches to TERT targeting include 
use of the small molecular inhibitor imetelstat (GRN163L), 
immunotherapy, GABPβ1L inhibition, as well as targeting 
RdRP activity of TERT using eribulin (Figure 3).
Imetelstat
Imetelstat is the only small molecule inhibitor of TERT to 
be evaluated in clinical trials.24 Imetelstat is a 13-bp RNA 
oligonucleotide with a thio-phosphramidate backbone that 
allows for the formation of RNA duplexes.68 The molecule 
also contains a lipid moiety that increases cellular uptake 
and retention.69 Unlike traditional antisense oligonucleo-
tides, imetelstat was not designed to bind to mRNA but 
rather to bind to TERT.24 In vitro studies demonstrated te-
lomerase inhibition with concomitant telomere shortening 
in several cell lines including tumors of the bladder, breast, 
lung, liver, prostate, and pancreas. In vivo studies using 
mouse xenograft lung cancer models showed similar re-
sults, in addition to reduced tumor growth and metastasis 
and increased sensitivity to chemotherapy.24,70
In vitro studies of a glioblastoma cell line by Marian 
et al.71 found that imetelstat produced a dose-dependent 
inhibition of telomerase, with long-term treatment 
leading to progressive telomere shortening, decreased 
proliferation, and cell death in glioblastoma tumor-
initiating cells. Furthermore, combining treatment with 
  












Cancer cell Activated T cell
MHC TCR
Fig. 3 Treatment strategies for TERT promoter mutant tumors. Various treatment strategies taking advantage of the presence of TERT pro-
moter mutations have been proposed, including targeting the GABPβ1L tetramers that bind to the mutant promoter sites as transcription factors, 
blocking the TERT active site using small molecule inhibitors such as Imetelstat that bind to TERC, inhibition of RNA-dependent RNA polymerase 
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radiation and temozolomide reduced cancer cell survival 
and enhanced activation of the DNA damage response 
pathway. In vivo studies using mouse xenograft glioblas-
toma models revealed that imetelstat is able to cross the 
blood-brain barrier with 70% inhibition of telomerase ac-
tivity and reduced growth of subcutaneously implanted 
tumors. While some imetelstat clinical trials have been 
completed, some have been suspended due to hema-
tological toxicity.24 A  phase 2 clinical trial investigating 
imetelstat use for recurrent pediatric primary glial neo-
plasms showed 95% inhibition of intratumoral telom-
erase activity, but also showed significant hematological 
toxicity and was halted due to 2 patient deaths related to 
intratumoral intracranial hemorrhage.72
Immunotherapy
Cancer cells express protein fragments of telomerase 
as cell surface antigens via the human leukocyte antigen 
(HLA) class I pathway.73,74 These epitopes can be targeted 
by cytotoxic T cells to kill cancer cells. The goal of anti-
telomerase immunotherapy is to sensitize the immune 
system to tumor cells expressing TERT epitopes, resulting 
in the activation of T cells.
One strategy used to achieve this goal is the develop-
ment of TERT vaccines. Two vaccines have been used to 
generate an anti-telomerase response in cancer cells: 
GV1001 and Vx001. GV1001 is a 16-amino acid, HLA 
class  II-restricted peptide that contains a part of the 
amino acid sequence of the TERT active site. Once in-
jected, the vaccine is processed endogenously to yield 
an HLA class  I  peptide as well. This vaccine therefore 
activates a CD4+ and a CD8+ cellular response. Phase II 
trials investigating GV1001 alone or in combination with 
other therapies have been completed for malignant mel-
anoma and hepatocellular carcinoma. Phase III GV1001 
trials are ongoing for non-small cell lung carcinoma and 
metastatic pancreatic cancer. Vx001 is a cryptic peptide 
vaccine containing a TERT amino acid sequence hidden 
within a protein structure. Endogenous processing of 
the peptide results in the HLA class I presentation with a 
CD8+ T-cell response. A phase 2 trial investigating Vx001 
in non-small cell lung cancer is currently ongoing.
Another strategy is to prime antigen-presenting den-
dritic cells ex vivo and then inject the primed cells back into 
the patient. GRNVAC1 is a dendritic cell vaccine consisting 
of autologous dendritic cells transduced with mRNA-
encoding TERT and LAMP1, which guides TERT proteins 
into lysosomes for breakdown and presentation. This re-
sults in a polyclonal immune response when the primed 
dendritic cells are injected back into the patient. One phase 
2 trial for GRNVAC1 in acute myelogenous leukemia has 
been completed. All 3 TERT vaccines have been shown to 
be well tolerated in cancer patients, with little effect on 
normal cells and no autoimmunity.24
GABPβ1L Inhibition
Recently, Mancini et  al.75 demonstrated that disrup-
tion of the β1L isoform of GABP reverses the replicative 
immortality of glioblastoma cells in a TERT promoter 
mutation-dependent manner. As previously discussed, 
the C228T and C250T mutations allow specifically for the 
binding of the heterotetramer form of the ETS transcrip-
tion factor GABP.30 GABPβ1L is a tetramer forming isoform 
of GABP that is not necessary for normal development 
but binds to the mutant TERT promoter site. The authors 
knocked down GABPβ1L in TERT promoter mutant gli-
oblastoma cells in vitro, resulting in decreased GABP 
binding, TERT expression, and cell viability. These effects 
of GABPβ1L knockdown were not seen in wildtype TERT 
promoter glioblastoma cells. Concordantly, knocking down 
GABPβ1L in a mouse xenograft model of glioblastoma 
impaired tumor growth and increased mouse survival.75 
Targeting GABPβ1L rather than TERT itself may repre-
sent a means of specifically targeting tumor cells bearing 
TERT promoter mutations while sparing normal cells, thus 
avoiding the hematopoietic side effects observed with 
drugs such as imetelstat.
Eribulin
Eribulin mesylate is a synthetic analog of halichondrin B, 
a natural isolate from marine sponges and was originally 
developed as an inhibitor of microtubule dynamics. In the 
United States, it is approved for the treatment of refrac-
tory metastatic breast cancer in patients who have pre-
viously received 2 or more chemotherapeutic agents.76 
Yamaguchi et  al.77 demonstrated that eribulin inhibited 
the growth of platinum-resistant ovarian cancer cells via 
inhibition of the RdRP activity, a non-telomere length-
ening role of TERT. In a xenotransplantation glioblas-
toma mouse model, intraperitoneal injection of eribulin 
led to a significant reduction in intracranial tumor growth 
demonstrating a promising role for this drug in glioblas-
toma treatment. A phase II trial in patients with recurrent 
glioblastoma treated postoperatively with temozolomide, 
radiation, and bevacizumab is currently ongoing in 
Japan.78
Conclusions
Telomeres protect the ends of chromosomes from deteri-
oration and end fusion to other chromosomes but shorten 
with successive mitotic cycles in normal cells. In highly 
replicative cells, the TERT expression maintains telomere 
length. TERT expression is otherwise very tightly regulated 
in normal somatic cells, with most cells silencing expression 
and entering a senescent state as their telomeres shorten. 
Two recurrent TERT promoter mutations have been de-
tected in many cancers. In glioblastoma, meningioma, and 
medulloblastoma, TERT promoter mutation frequency ap-
pears to increase with a worsening grade of tumor. In gli-
oblastoma, the mutational frequency is particularly high 
and the prognostic implications of the TERT mutation vary 
depending on the presence of other mutations. The un-
derlying biology explaining these survival differences is 
poorly understood and warrants further investigation. 
Nevertheless, the clinical significance of TERT mutation 
highlights the importance of annotating its status in every 








niversity School of M
edicine Library user on 17 O
ctober 2020











maintenance are not currently part of standard-of-care regi-
mens, but several candidates are undergoing clinical trials. 
While promising, targeting TERT is not without challenges. 
The treatment effect is dependent on telomere shortening 
that only occurs after several mitotic cycles. Furthermore, 
rapidly dividing cells, such as hematopoietic cells, de-
pend on TERT activity and are sensitive to its inhibition. 
Ultimately, many aspects of TERT function and regulation 
remain unknown. More recently, there is mounting evidence 
that TERT has functions other than telomere elongation and 
may play other roles such as regulating gene expression, 
mitochondrial activity, epithelial–mesenchymal transitions, 
and DNA damage repair. As our understanding of the role of 
telomeres and TERT in cancer biology improves, more ther-
apeutic opportunities will likely be identified.
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